C-peptide antibodies induced by bovine insulin therapy.
Antibodies reactive with the C-peptide portion of proinsulin can be detected in the sera of patients on conventional bovine insulin regimes which include the soluble form. Direct and competitive binding studies demonstrate that C-peptide antibodies show species specificity but do not recognize free homologous C-peptide. This is likely to be due to conformational change following cleavage of C-peptide from the proinsulin molecule. Examination of sera from a large group of patients established on a standard insulin regime shows that C-peptide and insulin antibody levels do not correlate with each other and are likely to show different patterns of genetic control.
D000818:Animals; D000918:Antibody Specificity; D002096:C-Peptide / Q000276:immunology*; D002417:Cattle; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000096:biosynthesis*; D007336:Insulin, Isophane / Q000627:therapeutic use; D049528:Insulin, Long-Acting / Q000627:therapeutic use; D010455:Peptides / Q000276:immunology*
D002096:C-Peptide; D007328:Insulin; D007330:Insulin Antibodies; D049528:Insulin, Long-Acting; D010455:Peptides; D007336:Insulin, Isophane